Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Genome wide CRISPR screen for BET inhibitor resisatnce in OCI-AML2 cells using Y. Kosuke library

ABSTRACT: Genome wide CRISPR screen for BET inhibitor resisatnce in OCI-AML2 cells using Y. Kosuke library

PROVIDER: PRJNA670198 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR12850558.fastq.gz	Fastqsanger.gz
	SRR12850559.fastq.gz	Fastqsanger.gz
	SRR12850560.fastq.gz	Fastqsanger.gz
	SRR12850561.fastq.gz	Fastqsanger.gz
	SRR12850562.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 22

Similar Datasets

Genome wide CRISPR screen for BET inhibitor resisatnce in OCI-AML2 cells using Y. Kosuke library

Project description:OCI-AML2 BETi-naive or JQ1 resistant cells were infected with CRISPR/Cas9 library, selected for puromycin resistance for integration events and exposed to JQ1/CPI-0610 or vehicle, DMSO, at 200nanoMolar for JQ1 and 500nanoMolar CPI-0610 concentrations. Cells were collected at time 0 (post puromycin selection), day 14 JQ1 and 21 CPI-0610 , DNA was extracted and sgRNA barcodes were amplified. PCR library was deep sequenced using highthroughput Illumina platform Hiseq using 6 samples per lane.

2023-10-13 | GSE159689 | GEO

Genome wide CRISPR screen for Venetoclax plus Ruxolitinib combination resistance in OCI-AML2 cells using Y. Kosuke library

Project description:30 million OCI-AML2 cells were infected with CRISPR/Cas9 library, selected for puromycin resistance for integration events and exposed DMSO, venetoclax (0.5 uM) or venetoclax (0.1 uM) plus ruxolitinib (1 uM). Cells were collected at day 14 and 21 , DNA was extracted and sgRNA barcodes were amplified. PCR library was deep sequenced using Novaseq 6000 high throughput Illumina platform.

2023-06-30 | GSE216087 | GEO

Genome wide CRISPR screen for Venetoclax plus Ruxolitinib combination resistance in OCI-AML2 cells using Y. Kosuke library

Project description:Genome wide CRISPR screen for Venetoclax plus Ruxolitinib combination resistance in OCI-AML2 cells using Y. Kosuke library

| PRJNA892071 | ENA

Genome wide CRISPR screen for CG-806 resistance in OCI-LY3 cells using Y. Kosuke library

Project description:OCI-LY3 cells were infected with CRISPR/Cas9 library, selected for puromycin resistance for integration events and exposed to CG-806 or vehicle, DMSO, at 1 microMolar concentrations. Cells were collected at time 0 (post puromycin selection) and day 7. DNA was extracted and sgRNA barcodes were amplified. PCR library was deep sequenced using highthroughput Illumina platform Novaseq 6000.

2023-05-04 | GSE174766 | GEO

Genome wide CRISPR screen for CG-806 resistance in OCI-LY3 cells using Y. Kosuke library

Project description:Genome wide CRISPR screen for CG-806 resistance in OCI-LY3 cells using Y. Kosuke library

| PRJNA731487 | ENA

Genome wide CRISPR screen for Trametinib sensitivity in resistant MOLM13 cells using Y. Kosuke library

Project description:Cas9-expressing trametinib resistant MOLM-13 cell lines (TM1) were generated using the Cas9-Blst (Addgene, #52962) and expanded for genome-wide loss-of-function screens using the Y. Kosuke library (Addgene, #67989) Following transduction, cells cultured in the presence of trametinib (100 nM) or DMSO after lentiviral infection.

2024-02-22 | GSE235183 | GEO

RNA-seq expression profiling of OCI-AML2 and OCI-AML3 cells upon CRISPR/Cas9 –mediated disruption of DDX3X RNA binding domain

Project description:Human acute myeloid leukemia cell lines OCI-AML2 and OCI-AML3 were used in a CRISPR/Cas9-mediated approach to specifically target DDX3X’s gene sequences encoding the RNA binding domain of the helicase. DDX3X RNA binding domain is bipartite in the two halves of the helicase core. sgRNAs were designed to target both halves of the domain (named RNA binding domain A and B – RBDA and RBDB). We performed RNA-seq to observe the gene expression changes in both OCI-AML2 and OCI-AML3 cell lines following the not-combined CRISPR/Cas9 –mediated targeting of both regions of the DDX3X RNA binding domain. Control CRISPR/Cas9 performed with no sgRNA expressing vector (named “empty vector”) was performed in both cell lines. The latter condition was used as a control for gene expression changes analysis, for each cell line.

2019-11-23 | E-MTAB-6241 | biostudies-arrayexpress

Transcription profiling of human acute myeloid leukemia cell line OCI/AML2 with the anti-parasitic ivermectin

Project description:OCI AML2 cells were treated with the anti-parasitic ivermectin (single dose, two time points) in order to assess gene expression changes.

2010-01-06 | E-MEXP-2528 | biostudies-arrayexpress

Genome wide CRISPR screen for Venetoclax resisatnce in MOLM13 cells using Y. Kosuke library

Project description:Genome wide CRISPR screen for Venetoclax resisatnce in MOLM13 cells using Y. Kosuke library

| PRJNA540211 | ENA

Genome wide CRISPR screen for Trametinib sensitivity in resistant MOLM13 cells using Y. Kosuke library

Project description:Genome wide CRISPR screen for Trametinib sensitivity in resistant MOLM13 cells using Y. Kosuke library

| PRJNA984725 | ENA